211 related articles for article (PubMed ID: 21781137)
1. Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice.
Soudi S; Hosseini AZ; Hashemi SM
Parasite Immunol; 2011 Oct; 33(10):561-71. PubMed ID: 21781137
[TBL] [Abstract][Full Text] [Related]
2. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
[TBL] [Abstract][Full Text] [Related]
3. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
[TBL] [Abstract][Full Text] [Related]
4. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.
Tafaghodi M; Eskandari M; Khamesipour A; Jaafari MR
Exp Parasitol; 2011 Oct; 129(2):107-14. PubMed ID: 21767536
[TBL] [Abstract][Full Text] [Related]
5. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
6. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
8. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
9. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
10. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
Nagill R; Mahajan R; Sharma M; Kaur S
Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
12. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
Li J; Nolan TJ; Farrell JP
Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
[TBL] [Abstract][Full Text] [Related]
13. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen.
Badiee A; Khamesipour A; Samiei A; Soroush D; Shargh VH; Kheiri MT; Barkhordari F; Robert Mc Master W; Mahboudi F; Jaafari MR
Exp Parasitol; 2012 Dec; 132(4):403-9. PubMed ID: 22982807
[TBL] [Abstract][Full Text] [Related]
14. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
15. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
[TBL] [Abstract][Full Text] [Related]
16. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
[TBL] [Abstract][Full Text] [Related]
17. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis.
Michel MY; Fathy FM; Hegazy EH; Hussein ED; Eissa MM; Said DE
J Egypt Soc Parasitol; 2006 Apr; 36(1):159-76, following 76. PubMed ID: 16605109
[TBL] [Abstract][Full Text] [Related]
18. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
[TBL] [Abstract][Full Text] [Related]
19. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
